

PARTICIPANTS, PRESENTATIONS, AND POSTER SESSIONS



Scientific & Education Committee / Chair Members

CHAIRS

Friday, June 2

6:00 pm – 8:00 pm, Marriott Marquis,
Atlanta, Georgia

Michael Heinrich, M.D.

Exploring the Use of Targeted Therapies:
New Therapies, New Techniques, New Approaches
Co-Chair Satellite Symposium

Saturday, June 3

8:00 am – 9:15 am, Bldg C, Level 2,
Room C208

Craig Nichols, M.D.

Management of Difficult Germ Cell Tumors
Chair – Clinical Problems in Oncology

2:00 pm – 6:00 pm, Bldg C, Level 3,
Room C303 & C307

Mark Garzotto, M.D.

Genitourinary (Non Prostate) Poster
Discussion Chair
Chair Poster Discussion

Sunday, June 4

4:30 pm – 6:00 pm, Bldg B, Level 5,
Thomas B. Murphy Ballroom 3

Charles Blanke, M.D.

Is Metastatic Colon Cancer Curable?
Chair Clinical Science Symposium

Monday, June 5

8:00 am – 9:15 am, Bldg C, Level 2, Room C208

Craig Nichols, M.D.

Management of Difficult Germ Cell Tumors
Chair – Clinical Problems in Oncology

2:00 pm – 6:00 pm, Bldg, B, Level 4, Room B401 & B406

Tomasz Beer, M.D.

Genitourinary (Prostate Cancer) Poster
Discussion Chair
Chair Poster Discussion

COMMITTEE MEMBERS

Tomasz Beer, M.D., Scientific Program Committee

Charles Blanke, M.D., Education Committee for Lower G.I.

Mark Garzotto, M.D., Scientific Program Committee

Charles Lopez, M.D., Ph.D., Member Tumor Biology
Cancer Education Committee

NOTES

Presenters

Friday, June 2

2:30 pm – 5:30 pm, Bldg C, Level 2, Room C208

Craig R. Nichols, M.D.

Career Choices: Options in Academia, Private Practice, Industry, and Government (ES06)

Educational Symposium

6:00 pm – 8:00 pm, Marriott Marquis, Atlanta, Georgia

Michael Heinrich, M.D.

Targeted Therapies: Where Did We Start? Where Are We Now, Where Are We Going?

Satellite Symposium

Saturday, June 3

8:00 am – 9:30 am, Bldg A, Level 4, Room A411

Michael Heinrich, M.D.

Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status (Abstract #9502)

Clinical Science Symposium

1:15 PM – 2:30 pm, Bldg A, Level 4, Room A405

Michael Heinrich, M.D.

Christopher Corless, M.D., Ph.D.

Technology Primer for Oncologists: Cell Signaling Pathways and Proliferation.

Meet the Professor Session

3:00 pm – 6:00 pm, Bldg C, Level 3, Georgia Ballroom 2

Brian Druker, M.D., Ph.D.

Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study. (Abstract 6506)

Oral Presentation

Sunday, June 4

10:00 am – 1:00 pm, Bldg C, Level 1, Hall C3

Craig R. Nichols, M.D.

Genitourinary Cancer (Prostate and Testes)

Oral Presentation

10:00 am – 1:00 pm, Bldg C, Level 1, Hall C3

Tomasz Beer, M.D.

Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT (Abstract #4518)

Oral Presentation

4:30 pm – 6:00 pm, Bldg C, Level 1, Hall C3

Tomasz Beer, M.D.

Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: Hypothesis for a new class of anticoagulants

Clinical Science Symposium

Monday, June 5

10:00 am – 1:00 pm, Bldg C, Level 1, Hall C4

Christopher Ryan, M.D.

Sorafenib plus interferon-2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412 (Abstract 4525)

Oral Presentation

11:30 am – 12:45 pm, Bldg A, Level 4, Room A402

Michael Heinrich, M.D.,

Christopher Corless, M.D., Ph.D.

Technology Primer for Oncologists: Cell Signaling Pathways and Proliferation.

Meet the Professor Session

Poster Sessions

Saturday, June 3

8:00 am – 12:00 pm, Bldg B, Level 1, Hall B5

Poster #P4

Rachel Sanborn, M.D.

A phase II study of celecoxib © with irinotecan (I), 5-fluorouracil (F), and leucovorin (L) in patients (pts) with advanced or metastatic colorectal cancer (CRC) (Abstract 3588)

General Poster Session

8:00 am – 12:00 pm, Bldg B, Level 1, Hall B5

Poster # G12,

Charles Thomas, Jr., M.D.,

SJ Wang, M.D.

Conditional survival in gall bladder carcinoma: Results from the SEER 11 datasets (Abstract 4130)

General Poster Session

Sunday, June 4

9:00 am – 2:15 pm, Bldg C, Level 3,

Room C306

Poster #14

Charles Blanke, M.D.

Long-term follow-up of a phase II randomized trial advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. (Abstract 9528)

Poster Discussion

2:00 pm – 6:00 pm, Bldg B, Level 1, Hall B5

Poster #H2

Mark Garzotto, M.D.

Effect of obesity on PSA density (PSAD): a new clinical predictor of prostate cancer. (Abstract 4617)

General Poster Session

2:00 pm – 6:00 pm, Bldg B, Level 1, Hall B5

Poster #G8

Julie Graff, M.D., Tomasz Beer, M.D.

Predictors of overall and cancer-specific survival in patients with clinically localized prostate cancer (PC) treated with primary androgen deprivation therapy (PADT): Results from the Prostate Cancer Outcomes Study (Abstract #4610)

General Poster Session

2:00 pm – 6:00 pm, Bldg B, Level 1, Hall B5,

Poster #H4,

Arthur Hung, M.D., Luciana DePaula, M.D.,

Mark Garzotto, M.D.

Pre-treatment PSA Velocity (PSAV) is not predictive of outcomes after radical prostatectomy (RP) in a referral cohort. (Abstract 4619)

General Poster Session

2:00 pm – 6:00 pm, Bldg B, Level 1, Hall B5

Poster #G12

Joseph Chan, M.D., Christopher Ryan, M.D.

Tomasz Beer, M.D.

Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: results from ASCENT (Abstract #4614)

General Poster Session

2:00 pm – 6:00 pm, Bldg B, Level 1, Hall B5

Poster #J5,

Catherine O'Brien, M.D.

Assessment of PSA and digital rectal examination (DRE) for the detection of Gleason ≥ 7 prostate cancer in a referral population. (Abstract 4633)

General Poster Session

2:00 pm – 6:00 pm, Bldg B, Level 1, Hall B5,

Poster #H12

Tomasz Beer, M.D. (Co-Author)

Diethylstilbestrol and docetaxel; a phase II study in patients with metastatic, androgen independent prostate cancer. (Abstract 4627)

General Poster Session

